U.S. President Donald Trump and Israeli Prime Minister Benjamin Netanyahu hold a press conference after meeting at Trump’s Mar-a-Lago club in Palm Beach, Florida, U.S., Dec. 29, 2025. Jonathan Ernst | Reuters Israeli Prime Minister Benjamin Netanyahu will meet with U.S. President Donald Trump in Washington on Wednesday about American talks with Iran, his office said Saturday, while Iran's foreign ...
U.S. President Donald Trump and Israeli Prime Minister Benjamin Netanyahu hold a press conference after meeting at Trump’s Mar-a-Lago club in Palm Beach, Florida, U.S., Dec. 29, 2025. Jonathan Ernst | Reuters Israeli Prime Minister Benjamin Netanyahu will meet with U.S. President Donald Trump in Washington on Wednesday about American talks with Iran, his office said Saturday, while Iran's foreign minister threatened U.S. military bases in the region a day after the discussions. "The prime minister believes that all negotiations must include limiting the ballistic missiles, and ending support for the Iranian axis," Netanyahu's office said in a brief statement, referring to Tehran's support for militant groups, including Hezbollah in Lebanon and Hamas in the Palestinian territories. Trump and Netanyahu last met in December. There was no immediate White House comment. The U.S. and the Islamic Republic of Iran held indirect talks on Friday in Oman that appeared to return to the starting point on how to approach discussions over Tehran's nuclear program. Trump called the talks "very good" and said more were planned for early next week. Washington was represented by Middle East special envoy Steve Witkoff and Jared Kushner , Trump's son-in-law. Trump has repeatedly threatened to use force to compel Iran to reach a deal on its nuclear program after sending the aircraft carrier USS Abraham Lincoln and other warships to the region amid Tehran's crackdown on nationwide protests that killed thousands. Gulf Arab nations fear an attack could spark a regional war, with memories fresh of the 12-day Israel-Iran war in June. For the first time in negotiations with Iran, the U.S. on Friday brought its top military commander in the Middle East to the table. U.S. Navy Adm. Brad Cooper, head of the military's Central Command, then visited the USS Abraham Lincoln on Saturday with Witkoff and Kushner, the command said in a statement. Iranian Foreign Minister Abbas Araghchi told journalist...
It’s refreshing, groundbreaking and absolutely piles up the gags. The return of this Glaswegian sitcom is very welcome indeed The second series of Dinosaur opens on the Isle of Wight – a mere seven-hour drive and ferry ride away from our heroine’s beloved Glasgow. Oh dear. Nina (Ashley Storrie) is eight months into a dig, the job she took at the end of series one, and despite discovering a metazoi...
It’s refreshing, groundbreaking and absolutely piles up the gags. The return of this Glaswegian sitcom is very welcome indeed The second series of Dinosaur opens on the Isle of Wight – a mere seven-hour drive and ferry ride away from our heroine’s beloved Glasgow. Oh dear. Nina (Ashley Storrie) is eight months into a dig, the job she took at the end of series one, and despite discovering a metazoic dung beetle and getting pally with a big American fella called Clayton who is so charming he can call her “Scotland” and get away with it, she’s homesick. She is missing Lee, her almost-sort-of boyfriend who used to make her morning coffee outside the Kelvingrove Art Gallery and Museum, where she worked in the palaeontology department ( not with the dirty grave robbers over in antiquities). She is missing watching The Real Housewives with her sister, Evie, their takeaway Tuesdays and walks around the “wee dodgy parks in case we uncover a homicide”. She’s all set to go home when she is asked to stay on another year. Will she choose her precious old rocks, or head to the exact midpoint between the Isle of Wight and Glasgow to reunite with Lee? So begins the madcap rush (in a very slow buggy) to a park bench in Knutsford, and the happy return of this hilarious, heartwarming and covertly groundbreaking sitcom. Continue reading...
Sector mix, volatility, and costs shape the risk profiles of these leveraged ETFs. Here's what sets them apart for long-term investors. The ProShares - Ultra QQQ ETF (QLD +4.16%) and the ProShares - Ultra S&P 500 ETF (SSO +3.87%) both seek to double the daily returns of major U.S. equity indexes using leverage, but SSO tracks the S&P 500 while QLD tracks the Nasdaq-100. This comparison explores th...
Sector mix, volatility, and costs shape the risk profiles of these leveraged ETFs. Here's what sets them apart for long-term investors. The ProShares - Ultra QQQ ETF (QLD +4.16%) and the ProShares - Ultra S&P 500 ETF (SSO +3.87%) both seek to double the daily returns of major U.S. equity indexes using leverage, but SSO tracks the S&P 500 while QLD tracks the Nasdaq-100. This comparison explores the trade-offs between the two, including expenses, risk, recent returns, and portfolio makeup. Snapshot (cost & size) Metric SSO QLD Issuer ProShares ProShares Expense ratio 0.87% 0.95% 1-yr return (as of Feb. 2, 2026) 23.67% 29.85% Dividend yield 0.68% 0.17% Beta (5Y monthly) 2.03 2.35 AUM $8 billion $11 billion QLD charges a slightly higher expense ratio than SSO, making it less affordable for cost-conscious investors. SSO also offers a notably higher dividend yield, which may appeal to those seeking income from their leveraged ETF exposure. That said, leveraged ETFs typically work best as short-term investments, so factors like fees and dividend income may not be top priority. Performance & risk comparison Metric SSO QLD Max drawdown (5 y) -46.73% -63.68% Growth of $1,000 over 5 years $2,601 $2,403 What's inside QLD aims to deliver twice the daily return of the Nasdaq-100 Index, allocating 53% of the portfolio to technology, 17% to communication services, and 13% to consumer cyclical stocks. With 101 companies, its top positions are Nvidia, Apple, and Microsoft, reflecting a strong tilt toward large-cap tech. The fund's daily leverage reset means performance can diverge from expectations over periods longer than a single day, especially in volatile markets. SSO, by contrast, tracks the S&P 500 with 503 holdings, offering a broader sector mix of 35% technology, 13% financial services, and 11% communication services. Its largest positions are also Nvidia, Apple, and Microsoft, but with slightly lower weights. Like QLD, SSO resets its leverage daily, introducing similar comp...
Young America's Affordability Crisis Has Political Consequences Authored by Micky Horstman via RealClearPolitics , One and a half million more young adults live with their parents today than a decade ago . They’re losers … economically. Since the pandemic, fair market rents have increased as much as 40% in Chicago, the cost of owning a car is up more than 40%, and car insurance and health care pri...
Young America's Affordability Crisis Has Political Consequences Authored by Micky Horstman via RealClearPolitics , One and a half million more young adults live with their parents today than a decade ago . They’re losers … economically. Since the pandemic, fair market rents have increased as much as 40% in Chicago, the cost of owning a car is up more than 40%, and car insurance and health care prices have spiked . Student loan debt has quadrupled since 2000, and entry-level wages haven’t kept pace with inflation. For young people without financial or family support, it’s an affordability crisis that feels insurmountable . Cost of living was Gen Z’s top political issue in 2024; they feel the “American Dream” slipping farther away. And it’s driving them to the extremes. While political pundits insist Gen Z is “more well-off,” than other generations, and reporters write about “ the big myth of zoomers’ economic conditions ” – pointing to rising wealth and low unemployment compared to previous generations – political extremists from Democratic Socialist Hasan Piker to far-right nationalist Nick Fuentes are validating the distressed generation narrative. As Gen Z flocks to the fringes, it’s on lawmakers to bring them back and renew their belief in the American Dream. They can do this by repairing the systems holding young people back, not pushing populist quick fixes or pretending these lived experiences aren’t real. Wealth rises when you’re living in your childhood bedroom. Low unemployment doesn’t matter if jobs on the market are temporary, low-wage, or evaporate the moment the economy hiccups or AI replaces you. The kids are scared. The far right blames immigrants. The far left blames billionaires. Leaders propose handing out $25,000 in down-payment support or mass deportations to solve the youth’s housing problems. These extremes are wrong. The reality is: Government regulations have spiked costs and killed opportunities for young people. For years, lawmakers infused...
調查：三分二濕疹患者曾用艾草浸浴等偏方 近半病情惡化 醫生籲勿亂試 To view this video please enable JavaScript, and consider upgrading to a web browser that supports HTML5 video 【有線新聞】有調查發現，三分二受訪濕疹患者曾經採用偏方治療令病情惡化。濕疹關注組去年底以問卷訪問二百多名濕疹患...
調查：三分二濕疹患者曾用艾草浸浴等偏方 近半病情惡化 醫生籲勿亂試 To view this video please enable JavaScript, and consider upgrading to a web browser that supports HTML5 video 【有線新聞】有調查發現，三分二受訪濕疹患者曾經採用偏方治療令病情惡化。濕疹關注組去年底以問卷訪問二百多名濕疹患者，七成人正接受保濕潤膚膏治療，過半使用外用類固醇，近半人覺得療效短暫。有三分二受訪患者，承認曾經採用沒有醫學實證的偏方治療，包括購買所謂「藥物」、麥皮水沖身、艾草浸浴等。當中47%稱延誤了治療黃金期，令病情惡化。 有專科醫生稱，濕疹不單是敏感和皮膚問題，而是免疫系統失調，應尋求專科治療。皮膚及性病科專科醫生鍾文浩：「我們知道患者擔心費用高昂，確實是，但如果你把錢花在無效的方法上，同樣也花錢。及早將金錢用在合適的地方、治療，整體是節省了。及早控制病情，受濕疹影響的時間會縮短，盡早尋找適合的醫生，不要真的去尋求所謂的另類醫學。」
Recent Medicare Advantage news may mean disappointing updates to guidance. CVS Health (CVS +2.65%) will release its latest quarterly results and provide guidance updates pre-market on Tuesday, Feb. 10. Over the past four quarters, the healthcare giant has delivered earnings results that finished well ahead of sell-side estimates. Yet even if CVS delivers a revenue and earnings beat in Q4, don't as...
Recent Medicare Advantage news may mean disappointing updates to guidance. CVS Health (CVS +2.65%) will release its latest quarterly results and provide guidance updates pre-market on Tuesday, Feb. 10. Over the past four quarters, the healthcare giant has delivered earnings results that finished well ahead of sell-side estimates. Yet even if CVS delivers a revenue and earnings beat in Q4, don't assume that what comes next is a post-earnings rally. Instead, it's possible that updates to 2026 guidance, affected by the recent proposed Medicare Advantage payment rates for this year, will lead to a negative response among investors. This comes even as this healthcare stock has already been subject to near-term volatility on the Medicare news, falling by double-digit percentages upon its announcement late last month. CVS Health earnings preview For Q4 2025, sell-side consensus calls for non-GAAP earnings of $0.99 per share. This represents a moderate decline from Q4 2024, when the company reported non-GAAP earnings of $1.19 per share. That said, walked-back expectations could give way to yet another earnings beat for CVS. Then again, it may not be the results themselves that Wall Street focuses on with the earnings report coming next week. Instead, much as with other major healthcare stocks, investors may place greater focus on CVS' 2026 guidance. They may particularly be looking at the effect of the aforementioned Medicare Advantage payment rates on this guidance. UnitedHealth (UNH +3.02%), which released earnings the same day the U.S. government proposed raising Medicare Advantage payment rates by only 0.9%, released an underwhelming outlook for the coming year. Even as CVS shares, which fell by over 14% on the Medicare Advantage news, may seem to already price in the effect of lower-than-expected payment increases on revenue and profitability, that may not necessarily be the case. That said, even if shares, which have started to bounce back from the recent sell-off, tr...
Key Points CVS Health next reports earnings pre-market on Feb. 10. Shares in the healthcare giant also fell on the latest Medicare Advantage payments news, which could affect the stock on earnings day. Although caution may be key ahead of earnings, recent developments do not necessarily shatter the long-term bull case. 10 stocks we like better than CVS Health › CVS Health (NYSE: CVS) will release ...
Key Points CVS Health next reports earnings pre-market on Feb. 10. Shares in the healthcare giant also fell on the latest Medicare Advantage payments news, which could affect the stock on earnings day. Although caution may be key ahead of earnings, recent developments do not necessarily shatter the long-term bull case. 10 stocks we like better than CVS Health › CVS Health (NYSE: CVS) will release its latest quarterly results and provide guidance updates pre-market on Tuesday, Feb. 10. Over the past four quarters, the healthcare giant has delivered earnings results that finished well ahead of sell-side estimates. Yet even if CVS delivers a revenue and earnings beat in Q4, don't assume that what comes next is a post-earnings rally. Instead, it's possible that updates to 2026 guidance, affected by the recent proposed Medicare Advantage payment rates for this year, will lead to a negative response among investors. Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » This comes even as this healthcare stock has already been subject to near-term volatility on the Medicare news, falling by double-digit percentages upon its announcement late last month. CVS Health earnings preview For Q4 2025, sell-side consensus calls for non-GAAP earnings of $0.99 per share. This represents a moderate decline from Q4 2024, when the company reported non-GAAP earnings of $1.19 per share. That said, walked-back expectations could give way to yet another earnings beat for CVS. Then again, it may not be the results themselves that Wall Street focuses on with the earnings report coming next week. Instead, much as with other major healthcare stocks, investors may place greater focus on CVS' 2026 guidance. They may particularly be looking at the effect of the aforementioned Medicare Advantage payment rates on this guidance. UnitedHe...
Block Inc. ( XYZ ) could slash up to 10% of its workforce as part of an overhaul. The company has told hundreds of employees they may be let go during their annual performance review, Bloomberg reported . Block is set to release its quarterly financial results after market close on Feb. 26. More on Block Block's Ambitious 2028 Target Requires Nearly Perfect Execution - Compelling Upside Ahead Bloc...
Block Inc. ( XYZ ) could slash up to 10% of its workforce as part of an overhaul. The company has told hundreds of employees they may be let go during their annual performance review, Bloomberg reported . Block is set to release its quarterly financial results after market close on Feb. 26. More on Block Block's Ambitious 2028 Target Requires Nearly Perfect Execution - Compelling Upside Ahead Block: Network Expansion And Neighborhoods Initiatives May Offset Effects Of Bleak Economy Block: A Promising Transformation Met With A Stretched Valuation Multiple Block exceeds $200B in global lending Trump bought bonds worth $51M since November
Md Saiful Islam Khan Roche ( RHHBY )-owned Genentech said that its multiple sclerosis asset fenebrutinib met its primary endpoint in a phase 3 trial. Fenebrutinib reduced the risk of disability progression by 12% compared to Ocrevus (ocrelizumab) as soon as 24 weeks in individuals with primary progressive multiple sclerosis. Genentech noted that clinical improvement was particularly notable in upp...
Md Saiful Islam Khan Roche ( RHHBY )-owned Genentech said that its multiple sclerosis asset fenebrutinib met its primary endpoint in a phase 3 trial. Fenebrutinib reduced the risk of disability progression by 12% compared to Ocrevus (ocrelizumab) as soon as 24 weeks in individuals with primary progressive multiple sclerosis. Genentech noted that clinical improvement was particularly notable in upper limb function. Fenebrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor, has a significant benefit over Ocrevus in that it is given as a pill. The candidate is also in two other phase 3 trials for relapsing multiple sclerosis. More on Roche Roche Holding AG (RHHBY) Q4 2025 Earnings Call Transcript Roche Holding AG 2025 Q4 - Results - Earnings Call Presentation Roche's Full-Year Earnings: Solid, No Alarms - Obesity Promise Makes The Buy Case ClearBridge International Growth ADR Strategy exits Linde, adds Roche in Q4 2025 Genentech in up to $1.7B RNAi licensing deal with SanegeneBio
Jeff Clark of TradeSmith discusses contrarian setups in oversold software, discounted Bitcoin, and Albertsons as rotation hits former leaders—plus why gold miners may be due for a pullback.
Jeff Clark of TradeSmith discusses contrarian setups in oversold software, discounted Bitcoin, and Albertsons as rotation hits former leaders—plus why gold miners may be due for a pullback.
The review was instigated in the light of fresh details emerging about Lord Mandelson's contact with Jeffrey Epstein in the latest release of files in the US, as well as a separate police investigation beginning in the UK, they said.
The review was instigated in the light of fresh details emerging about Lord Mandelson's contact with Jeffrey Epstein in the latest release of files in the US, as well as a separate police investigation beginning in the UK, they said.